Xu Q, Kan CX, Hou NN, Sun XD. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report. World J Clin Cases 2022; 10(6): 1909-1913 [PMID: 35317157 DOI: 10.12998/wjcc.v10.i6.1909]
Corresponding Author of This Article
Xiao-Dong Sun, MD, PhD, Associate Chief Physician, Department of Endocrinology and Metabolism, Clinical Research Center, The Affiliated Hospital of Weifang Medical University, No. 2428 Yu-he Road, Weifang 261031, Shandong Province, China. xiaodong.sun@wfmc.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 26, 2022 (publication date) through Oct 19, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu Q, Kan CX, Hou NN, Sun XD. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report. World J Clin Cases 2022; 10(6): 1909-1913 [PMID: 35317157 DOI: 10.12998/wjcc.v10.i6.1909]
World J Clin Cases. Feb 26, 2022; 10(6): 1909-1913 Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1909
Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
Qian Xu, Cheng-Xia Kan, Ning-Ning Hou, Xiao-Dong Sun
Qian Xu, Cheng-Xia Kan, Ning-Ning Hou, Xiao-Dong Sun, Department of Endocrinology and Metabolism, Clinical Research Center, The Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China
Author contributions: Xu Q and Kan CX contributed to the data curation, investigation. writing-original draft preparation; Hou NN contributed to the methodology, investigation, writing-reviewing and editing; Sun XD contributed to the supervision, writing-reviewing and editing, funding acquisition.
Supported byNational Natural Science Foundation of China, No. 81870593 and No. 82170865; and Quality Improvement of Postgraduate Education in Shandong Province, No. SDYAL19156.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Dong Sun, MD, PhD, Associate Chief Physician, Department of Endocrinology and Metabolism, Clinical Research Center, The Affiliated Hospital of Weifang Medical University, No. 2428 Yu-he Road, Weifang 261031, Shandong Province, China. xiaodong.sun@wfmc.edu.cn
Received: July 28, 2021 Peer-review started: July 28, 2021 First decision: October 25, 2021 Revised: October 26, 2021 Accepted: January 14, 2022 Article in press: January 14, 2022 Published online: February 26, 2022 Processing time: 210 Days and 13.7 Hours
Abstract
BACKGROUND
Maturity-onset diabetes of the young 3 (MODY3), caused by mutations in the HNF1A gene, is the most common subtype of MODY. The diagnosis of MODY3 is critical because a low dose of sulfonylurea agents can achieve glucose control.
CASE SUMMARY
We describe a patient with MODY3 involving a novel splicing mutation, in whom low-dose gliclazide was sufficient to control clinically significant hyperglycemia. Sanger sequencing identified a splicing HNF1A mutation in 12q24 NM_000545.5 Intron5 c.1108-1G>A. Glycemic control has been maintained without insulin therapy for 28 mo after the diagnosis of diabetes.
CONCLUSION
This case report highlights a novel HNF1A gene mutation in MODY3 that is responsive to sulfonylurea therapy.
Core Tip: We describe a patient with maturity-onset diabetes of the young 3 caused by a splicing mutation in intron 5 at position 24 of chromosome 12, where the base sequence was replaced from G to A, and the protein encoded was changed accordingly. Excellent blood glucose control can be achieved by using low-dose sulfonylureas.
